whether the inflammation is coming from cancer or arthritis, we could deliver the drug there,
Low Vitamin d linked to aggressive prostate cancer The development of effective cellular backpacks has broad potential,
Shay and Wright are co-senior authors of the study nduction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2deoxyguanosineappearing in Cancer Discovery. reatment with 6-thio
who is also associate director of the Harold C. Simmons Comprehensive Cancer Center. Cancer cells are protected from apoptosis by telomerase,
Telomerase has therefore been the subject of intense research as a target for cancer therapy.
"Since telomerase is expressed in almost all human cancers, this work represents a potentially innovative approach to targeting telomerase-expressing cancer cells with minimal side effects on normal cells,"continued Dr. Shay."
"We believe this small molecule will address an unmet cancer need in an underexplored area that will be rapidly applicable to the clinic
funded by the Movember Foundation and conducted by scientists at The Institute of Cancer Research (ICR) in London,
Their preliminary finding of a link between XRCC2 and platinum drug resistance was validated once they sequenced a sample from an additional platinum-resistant tumor. e have identified new potential driver mutations for this type of cancer
whose cancer progresses in spite of the best available treatments,"said Dr. Turnbull Despite the fact that testicular cancer responds well to chemotherapy,
and spread to other parts of the bodyften causing more pathological symptoms than the primary cancer from which the CTCS were derived.
which could yield important new insights into how different cancers spread.""Very little is known about CTC clusters and their role in the progression and metastasis of cancer.
This unique technology presents an exciting opportunity to capture these exceptionally rare groups of cells for further analysis in a way that is minimally-invasive,
"This is the kind of breakthrough technology that could have a very large impact on cancer research."
and melanoma cancers. The researchers observed CTC clusters ranging from 2-19 cells among 300%of the patients."
Dr. Toner and his colleagues went on to test the technique in a small trial of 60 patients with metastatic cancer.
31%of prostate and 30%of melanoma patientsuggestive of a greater role for CTC clusters in metastatic cancers than previously thought.
"Given the increasing number of cancer therapies that engage the immune system, the ability to monitor tumor-immune cell interactions via the blood could be of great value."
and to develop even better technologies to understand their biology in cancer metastasis. t
#Inexpensive Technique Developed to Manufacture Nanofibers Scientists at the University of Georgia say they have developed an inexpensive way to manufacture nanofibers,
#New Gene Subgroup Driving Aggressiveness in Prostate Cancer Identified Prostate cancer is the most commonly diagnosed malignancy among males within developed countries.
Most often the majority of prostate cancer is thought of as an organ-confined disease with little genetic variation.
Now, prostate cancer researchers in Canada have sketched a molecular portrait providing a complete picture of
as well as identifying a new gene subgroup acting as a molecular driver for tumor progression. ur research shows how prostate cancers can vary from one man to anotherespite the same pathology under the microscopes well as how it can vary within one man who may have multiple
"explained Robert Bristow, M d.,Ph d.,clinician-scientist at Princess Margaret Cancer Centre, Toronto and senior author on the study. hese sub-types may be important to determining the response to surgery or radiotherapy between patients."
"The findings from this study were published recently in Nature Genetics through an article entitled patial genomic heterogeneity within localized, multifocal prostate cancer.
The investigators carefully analyzed the genetic backgrounds of each tumor sample, assigning individual aggression scores to the discreet cancer foci regions they identified.
The data revealed that even small cancers within the prostate can contain very aggressive cells capable of varying long term disease prognosis.
"This discovery of a new prostate cancer-causing gene gives researchers a new avenue to explore the biology of the disease
. principal investigator at the Ontario Institute for Cancer Research and lead author on the current study."
"By showing that mutations in prostate cancer vary spatially in different regions of a tumor,
Dr. Bristow thinks that this study takes an important step forward in identifying new biomarkers for prostate cancer and developing novel treatment options for patients."
"Our findings suggest we are getting closer to subtyping prostate cancer based on which gene is present to determine a patients'disease aggression in terms of the risk of spread outside the prostate gland at time of treatment,
we hope to inform doctors and patients about specialized treatments for each prostate cancer patient. e
when oncologists at Memorial Sloan-Kettering Cancer Center (MSK) refused to prescribe Zaltrap (ziv-aflibercept) for metastatic colorectal cancer due to its initial $11, 000-per-month cost.
Cancer was the third most expensive category of specialty drugs last year measured per-member-per year, according to Express Scripts;
However, cancer accounts for 32%of drugs costing more than $100, 000 a year, and is among a handful of key drivers of rising costs here are drugs in cancer that may give five months of life in one indication and 12 days of life in another.
Yet payers are being asked to pay the exact same amount for both, Henry said June 3. hen you get to the point where you have orphan drug pricing for non-orphan drugs,
Cancer treatments marketed by eight companies accounted for six of the Top 25 Best-selling Drugs of 2014 as listed by GEN,
and its Genentech subsidiary from marketing the top three cancer treatments: Rituxan (rituximab, co-marketed with Biogen and ranked#4), Avastin (bevacizumab;#
"explained co-author Dr. Joseph Ready, Ph d.,professor of biochemistry and member of the Simmons Cancer Center at UT Southwestern Medical center.
and is associated with gastric cancer, the team discovered that epigenetic heterogeneity can quickly emerge as a single cell divides,
. Purdue's Walther Professor of Cancer Structural biology and professor of biological sciences and chemistry who leads the research team."
who also is deputy director of the Purdue University Center for Cancer Research e
#New Drug Prevents Cancer cells from Staging Last Stand Unlike many last stands in human history,
the last stands arranged by individual cancer cells often resist being overwhelmed, with dire consequences for cancer patients.
Such a coordinated attack could effectively overrun cancer before it could muster one last defense,
"The finding opens the door to a new way to attack cancer, "said Reuben Shaw, a senior author of the paper, professor in the Molecular and Cell biology Laboratory at the Salk Institute and a Howard hughes medical institute Early Career Scientist."
Our work provides the basis for a novel drug that will treat resistant cancer by cutting off a main tumor cell survival process. i
#Depersonalized Medicine Shows Promising Results Against Cancer Researchers at St louis University (SLU) say they have,
Unlike recent advances in personalized medicine that focus on specific genetic mutations associated with different types of cancer,
this research targets a broad principle that applies to almost every kind of cancer: its energy source.
"Targeting cancer metabolism has become a hot area over the past few years, though the idea is not new,"according to Dr. Burris.
"If the Warburg effect and lipogenesis are key metabolic pathways that drive cancer progression, growth, survival, immune evasion, resistance to treatment,
targeting glycolysis and lipogenesis could offer a way to stop a broad range of cancers.
Because the Warburg pathway is a feature of almost every kind of cancer, researchers are testing it on a number of different cancer models."
"It works in a wide range of cancers both in culture and in human tumors developing in animal models,"explained Dr. Burris."
"Some are more sensitive to it than others. In several of these pathways, cells had been reprogramed by cancer to support cancer cell growth.
This returns the metabolism to that of more normal cells.""In human tumors grown in animal models,
and colorectal cancers and, to a lesser degree, in ovarian and pancreatic cancers.""It also seems to work on glioblastoma,
an extremely difficult to treat form of brain cancer, though it isn't able to cross the brain-blood barrier very effectively.
it increases their effectiveness, in a mechanism apart from SR9243's own cancer fighting ability, added Dr. Burris B
San diego School of medicine and Moores Cancer Center led an international team that discovered that cancer stem cell properties are determined by epigenetic changes.
The team reports that Lysine-Specific Demethylase 1 (LSD1) turns off genes required to maintain cancer stem cell properties in glioblastoma, a highly aggressive form of brain cancer.
rather than specific DNA sequences, determines tumorigenicity in glioblastoma cancer stem cells.""One of the most striking findings in our study is that there are dynamic and reversible transitions between tumorigenic
whether or not glioblastoma cells can proliferate indefinitely as cancer stem cells is their relative abundance of LSD1,
turning off a number of genes required for maintaining cancer stem cell properties, including MYC, SOX2, OLIG2 and POU3F2."
In fact, this spare can help the genome steer clear of cancer. Various kinds of damage can happen to DNA,
which is a hallmark of cancer. One common way that our genetic material can be harmed is from a phenomenon called oxidative stress.
predominantly the G. In order to stay cancer-free, our bodies must repair this DNA. This is where the special vulnerability noted earlier comes in.
They scanned the sequences of known human oncogenes associated with cancer, and found that many contain the four G-stretches necessary for quadruplex formation
#New Cell Structure Finding Might Lead to Novel Cancer Therapies University of Warwick scientists in the U k. say they have discovered a cell structure
which could help researchers understand why some cancers develop. For the first time a structure called'the mesh'has been identified
which is found to change in certain cancers, such as those of the breast and bladder, according to Stephen Royle, Ph d.,team leader and associate professor and senior Cancer Research UK Fellow at the division of biomedical cell biology at Warwick Medical school."
"As a cell biologist you dream of finding a new structure in cells but it's so unlikely.
TACC3, is overproduced in certain cancers. When this situation was mimicked in the lab, the mesh and microtubules were altered
According to Emma Smith, Ph d.,from Cancer Research UK, his early research provides the first glimpse of a structure that helps share out a cell's chromosomes correctly
and it might be a crucial insight into why this process becomes faulty in cancer
#Cell cycle protein Reverses Metabolic Reprogramming of Cancer cells Understanding how cancers cells reprogram cellular metabolic pathways is critical toward the development of novel therapeutic compounds.
Cutting off a cancer cell ood supplyis a veritable lynchpin for the efficient removal of tumors and now researchers at the University of Texas MD Anderson Cancer Center believe they may have found a protein that serves that very function.
"We know that all cancers grow by learning how to reprogram their metabolism, "said senior author Mong-Hong Lee, Ph d,
. professor of molecular and cellular oncology at MD Anderson Cancer Center. ut exactly how this occurs has not been understood fully.
and reverses cancer metabolic reprogramming. 14-3-3s is part of a family of conserved regulatory molecules that are expressed in all eukaryotic cells.
and transmembrane receptors. 14-3-3s has been shown previously to regulate cancer genes, such as p53 and suppress tumor growth,
Additionally, 14-3-3s demonstrated a suppressive effect on cancer glycolysis, mitochondrial biogenesis, as well as a range of other major metabolic processes of tumors."
and loss of 14-3-3s expression is critical for cancer metabolic reprogramming.""The MD Anderson team is excited about the findings from this new study
which are linked closely to early embryonic development and to diseases such as cancer. In plants as in animals and humans, intricate molecular networks regulate important biological functions, such as development and stress responses.
but primarily due to clinical trial expenses related to its pipeline of product candidates, including its Hyperacute immunotherapy cancer programs and its IDO pathway inhibitor (indoximod) programs
advancing efforts to create blood for surgery and treat leukaemia and other cancers. His latest work continues in this same vein,
and led by The Institute of Cancer Research in London. It saw 436 patients suffering from inoperable skin cancers treated with a modified form of herpes virus called Talimogene Laherparepvec T-VEC.
when used in the less advanced stages of the cancer, suggesting that T-VEC could prove a valuable early treatment option for skin cancers that are unable to be removed by a surgeon.
#Pill on a string pulls early signs of cancer As with every form of the deadly disease,
early detection of oesophageal cancer is critical to recovery. The current approach of detecting the cancer through biopsy can be a little hit and miss,
so the University of Cambridge's Professor Rebecca Fitzgerald and her team have developed what they claim to be a more accurate tool for early-diagnosis. Billed as"a pill on a string,
According to Fitzgerald, the five-year survival rate for oesophageal cancer is only 13 percent, a fact
Between one and five of every 100 people with Barrett's oesophagus go on to develop oesophageal cancer.
Using biopsies to detect the pre-cancer condition is problematic for a couple of reasons. It requires trained scientists to pore over the samples looking for abnormalities,
The team's latest research into Barrett's oesophagus and oesophageal cancer was published in the journal Nature Genetics.
or READ more at Daily mail) Pass on the Good Newsbelow) TAGSBREAKTHROUGHHEALTHINNOVATIONMEDICALSCIENCEWELLNESS Cuban Cancer Vaccine Could Soon be Available in U s. May 20,
and dsync+(TITECH/Georgia Tech) Near real-time plasma disruption detection using ADIOS (Princeton Plasma Research Lab/ORNL) Automated microscopy image analysis for cancer detection,
#Machine that unboils eggs now being used to improve cancer treatment The device can rip things apart with great accuracy,
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
because earlier efforts to make such nanoparticles weren't able to produce the consistent shapes needed said Dr. Moritz Kircher a molecular imaging specialist at Memorial Sloan Kettering Cancer Center in New york city.
so that they were very likely to develop cancer and injected them with the nanostars. The particles spread thorough the bloodstreams of the mice and built up in the cancerous cells.
The nanostars could be important in treating people with cancers in which the dangerous cells are sometimes hard to see such as liposarcoma a cancer that arises in fat cells.
You go in and open up the abdomen say and see all that fat Kircher said. You see some streaks that look abnormal
So doctors either have to take out all of the tissue that might possibly contain cancer or risk leaving some cancerous cells in the body.
The nanostars are nonspecific they don't need to be custom-made for each type of cancer. Earlier experiments with nanoparticles often required them to be built to order coated with proteins that would link to specific types of cancer cells.
For example, cancer researchers who want to deliver localized treatments to patients are using OWL's machines to build what Liverman called"microfluidic devices."
or try to figure out why only a fraction of patients"are helped by certain cancer treatments,
offering a view of the cellular morphology that can show signs of the presence of cancer.
Currently, samples are taken to the pathology lab to confirm that all of the cancer has been removed. This takes considerable time,
so that the cancer doesn come back while the patient is not left neurologically disabled. Tumors usually look the same as the healthy tissue just around them,
but the Hopkins team focused on brain cancer cellslack of myelin sheaths as the marker that influences how light passes through them.
Detection of human brain cancer infiltration ex vivo and in vivo using quantitative optical coherence tomographyource: Johns Hopkins Medicine
2015the Universitat Politcnica de Valncia is coordinating a European project to develop a device for the quick and early diagnosis of cancer March 7th,
New manufacturing unit increases production capacity 25 fold March 18th, 2015predicting prostate cancer: Nanotechnology shows promise for more accurate prostate cancer screening and prognosis March 17th, 2015'Additive manufacturing'could greatly improve diabetes management March 17th, 2015nanotechnology Drug Delivery Market in the US 2012-2016:
Latest Report Available by Radiant Insights, Inc March 16th, 2015discoveries 30 years after C60: Fullerene chemistry with silicon:
#Predicting prostate cancer: Nanotechnology shows promise for more accurate prostate cancer screening and prognosis Abstract:
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about
whether or not to undergo aggressive prostate cancer treatments. Technology developed by Northwestern University researchers may help solve that quandary by allowing physicians to identify which nascent cancers are likely to escalate into potentially life-threatening malignancies and
which ones will remain"indolent,"or nonaggressive. The prostate specific-antigen antigen (PSA) test was recommended once the screening tool for detecting prostate cancer,
but there is now disagreement over the use of this test because it can't predict which men with elevated PSA levels will actually develop an aggressive form of the disease."
if their cancer is dangerous and if they should seek treatment, "said Vadim Backman, senior author of the study."
"Right now there is no perfect tool to predict a prognosis for prostate cancer. Our research is preliminary,
Backman has been studying cell abnormalities at the nanoscale in many different types of cancers, using an optical technique he pioneered called partial wave spectroscopic (PWS) microscopy.
This is the first study to use PWS to predict a cancer prognosis, the likely course of the disease.
Prostate cancer is the second-leading cause of cancer deaths in American men, but doctors also say it is often overdiagnosed and overtreated.
By age 80, more than 50 percent of men will develop prostate cancer but not all will have the aggressive,
"The goal is to find specific biomarkers of aggressive cancers, "said Charles Brendler, MD, Co-Director of the John and Carol Walter Center for Urological Health & Program for Personalized Cancer Care at Northshore and author of the study."
"These biomarkers will allow us to individualize our treatment recommendations and improve patient outcomes.""To be able to give a patient a prognosis,
"This approach may allow tailoring of clinical decisions regarding management of patients with prostate cancer,
In this study, researchers analyzed prostate tissue biopsies from two cohorts of prostate cancer patients. The first cohort included eight men with non-progressing cancer
and 10 with progressing cancer. The PWS operator was blinded to the clinical status of the patients.
The second cohort was comprised of 10 progressors and 10 non-progressors in which the PWS investigators were blinded to the entire group.
This assessment may represent a powerful biomarker to predict cancer progression for men with early-stage prostate cancer."
Backman also hopes to use similar techniques to predict cancer progression in ovarian, breast and esophageal cancers.##
2015the Universitat Politcnica de Valncia is coordinating a European project to develop a device for the quick and early diagnosis of cancer March 7th,
2015sensors The Universitat Politcnica de Valncia is coordinating a European project to develop a device for the quick and early diagnosis of cancer March 7th,
2015military The Universitat Politcnica de Valncia is coordinating a European project to develop a device for the quick and early diagnosis of cancer March 7th,
2015the Universitat Politcnica de Valncia is coordinating a European project to develop a device for the quick and early diagnosis of cancer March 7th,
This could be especially beneficial to immunosuppressed individuals such as cancer patients. Administering a vaccine to protect against infection would overwhelm the patient's immune system.
#Microchip captures clusters of circulating tumor cells--NIH study Circulating tumor cells (CTCS) are cells that break away from a tumor and move through a cancer patient's bloodstream.
and researchers believe this is one mode by which cancer spreads. Even less common than single CTCS are small groups of CTCS, or clusters.
"Very little is known about CTC clusters and their role in the progression and metastasis of cancer.
M d."This is the kind of breakthrough technology that could have a very large impact on cancer research."
such as preventing cancer metastasis or precisely tailoring therapeutics to an individual's cancer cell biology. Toner and his collaborator Dr. Daniel Haber, M d.,Ph d.,also at MGH, recently used Cluster-Chip to capture
and melanoma cancers. The researchers found CTC clusters--ranging from two to 19 cells--in 30-40 percent of the patients."
This latter property makes the Cluster-Chip well-suited for capturing CTC clusters from a range of cancer types,
The researchers went on to test the Cluster-Chip in a small trial of 60 patients with metastatic cancer.
and an association between the presence of clusters and reduced survival in prostate cancer patients.
"Given the increasing number of cancer therapies that engage the immune system, the ability to monitor tumor-immune cell interactions via the blood could be of great value."
and to develop even better technologies to understand their biology in cancer metastasis
#Computing at the speed of light: Utah engineers take big step toward much faster computers The Utah engineers have developed an ultracompact beamsplitter--the smallest on record--for dividing light waves into two separate channels of information.
2015 Cancer becomes deadly when it spreads, or metastasizes. Not all cells have the same ability to travel through the body,
The differences in individual cancer cells are a key aspect of how cancer evolves becomes resistant to current therapies or recurs."
"says co-senior study author Sofia D. Merajver, M d.,Ph d.,scientific director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.
The researchers believe this type of device might some day help doctors understand an individual patient's cancer.
"In this work, extensive studies were performed on cell lines representing various types of cancer. The new device was designed to trace how cells move, sorting individual cells by their movement.
and appearance under the microscope of metastatic cells and expressed significantly higher levels of markers associated with metastatic cancer."
Patients seeking more information about their options for cancer treatment can call the U-M Cancer Answerline at 800-865-1125 5
2015effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015announcements SUNY Poly CNSE and NIOSH Launch Federal Nano Health and Safety Consortium:
2015effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015environment Nano-policing pollution May 13th, 2015chemists strike nano-gold:
2015nanomedicine Effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015nature inspires first artificial molecular pump:
2015effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015materials/Metamaterials Taking control of light emission:
Ljubimova, director of the Nanomedicine Research center in the Department of Neurosurgery and director of the Nanomedicine Program at the Samuel Oschin Comprehensive Cancer Institute, has received a $2. 5 million grant from the National institutes of health to continue the research.
or stop cancers by blocking them in multiple ways within the brain. The drug is about 20 to 30 nanometers in size-a fraction of a human hair,
and then fighting the cancer with precise, individualized tumor treatment. Researchers can determine tumor type by attaching a tracer visible on an MRI.
With the cancer's molecular makeup identified through this virtual biopsy, researches can load the"delivery system"with cancer-targeting components that specifically attack the molecular structure.
To show that the virtual biopsies could distinguish one cancer cell type from another, the researchers devised what is believed to be a unique method,
and lung cancers into laboratory mice to represent metastatic disease-with one type of cancer implanted on each side of the brain.
and attack the cancers. In each instance, animals that received treatment lived significantly longer than those in control groups."
"Several drugs are quite effective in treating different types of breast cancers, lung cancer, lymphoma and other cancers at their original sites,
but they are ineffective against cancers that spread to the brain because they are not able to cross the blood-brain barrier that protects the brain from toxins in the blood,
and the Samuel Oschin Comprehensive Cancer Institute contributed to the study with colleagues from the University of Southern California and Arrogene Inc,
The new NIH National Cancer Institute grant R01ca188743, will fund ongoing study.#####For more information, please click herecontacts:
The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists'ability to observe single molecules May 23rd,
The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists'ability to observe single molecules May 23rd, 2015aspen Aerogels to Present at the Cowen and Company Technology,
The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists'ability to observe single molecules May 23rd,201 0
"This is a versatile platform to carry a multitude of drugs-for melanoma, for other kinds of cancers and for other diseases,
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011